ReviewBlood advances2018

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Samantha M Jaglowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.